Maccura Biotechnology Co., Ltd. Class A

Maccura Biotechnology Co., Ltd. Class A

SSZSE:300463
8.57
CNY
-0.06
(-0.70%)
-0.07EPS
5.76BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.75
2.09
1.91
2.67
3.53
4.85
5.83
6.69
7.2
5.97
4.76
4.2
3.59
3.6
Basic EPS, GAAP
0.43
0.51
0.45
0.56
0.67
0.8
0.95
1.43
1.73
1.17
0.51
0.21
-0.06
-0.05
Free Cash Flow per Basic Share
-0.02
-0.1
-0.34
-0.61
-0.69
-0.61
-0.08
1.07
1.84
-0.24
0.04
-0.54
-0.24
- -
Dividend per Share
0.09
0.11
0.1
0.1
0.14
0.22
0.28
0.31
0.54
0.53
0.4
0.19
0.14
0.04
Book Value per Share
1.36
1.78
3.58
4.02
4.48
4.83
5.61
6.82
7.72
10.27
10.42
10.4
10.38
10.42
Tangible Book Value per Share
1.33
1.75
3.54
3.86
4.26
4.53
5.19
6.34
7.18
9.43
9.5
9.51
9.44
9.5
Basic Weighted Avg Shares
446
446
558
557
558
553
553
554
553
604
609
606
604
604
Sales/Revenue/Turnover
779
935
1,065
1,489
1,970
2,685
3,223
3,704
3,981
3,608
2,896
2,549
2,170
2,175
Operating Margin (%)
33.32
33.17
29.59
26.65
27.46
25.22
24.95
29.68
32.73
24.8
15.59
10.95
2.52
0.93
Depreciation Expense
30
41
53
72
100
122
155
205
236
270
313
337
369
- -
Net Income, GAAP
193
226
251
312
374
445
525
794
957
708
313
127
-36
-33
Effective Tax Rate (%)
20.33
20.32
17.01
17.92
18.58
19.07
18.39
15.3
15.57
11.07
0.23
4.72
- -
- -
Profit Margin (%)
24.78
24.2
23.57
20.96
18.99
16.57
16.3
21.43
24.03
19.63
10.8
4.98
-1.65
-1.51
Working Capital
317
524
1,490
1,358
1,488
1,577
1,687
2,215
2,542
3,614
3,102
2,444
2,175
2,411
LT Debt
- -
127
69
- -
120
250
200
349
441
301
175
191
526
600
Total Equity
604
792
2,000
2,283
2,613
2,865
3,328
4,005
4,542
6,529
6,611
6,424
6,306
6,333
Return on Invested Capital (%)
30.95
25.51
15.28
14.21
14.48
13.3
12.94
16.64
18.85
11.47
4.64
2.31
- -
- -
Return on Capital (%)
30.86
25.68
15.77
12.75
12.2
12.13
12.14
16.18
17.45
11.57
4.88
2.17
- -
- -
Return on Common Equity (%)
36.88
32.4
18.01
14.72
15.77
17.13
18.05
22.94
23.63
13.37
4.93
1.99
-0.57
-0.52

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
414
343
234
LT Borrowings
556
593
594
LT Finance Leases
4
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
605
605
605
Market Capitalization
6,482
4,995
5,762

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,199
3,124
3,181
Cash, Cash Equivalents & STI
767
814
894
Accounts Receivable, Net
1,053
1,054
1,058
Inventories
893
845
861
Total Current Liabilities
1,012
782
770
Payables & Accruals
- -
- -
- -
ST Debt
414
343
234
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.85%
10.75%
-1.84%
Free Cash Flow
-312.76%
-341.89%
-55.43%
Net Income, GAAP
-11.67%
-49.81%
-128.25%
Sales/Revenue/Turnover
9.49%
-9.69%
-14.84%
Total Cash Common Dividend
11.45%
-5.03%
-27.3%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
616
663
669
601
2,549
2025
510
565
- -
563
2,170
2026
475
559
579
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.13
0.13
-0.25
0.21
2025
0.04
0.02
- -
-0.12
-0.06
2026
0.01
0.04
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.16
0.01
0.19
2025
0.01
0.11
- -
0.01
0.14
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Ming Jian Wu
Full Time Employees
2,946
Sector
Health technology
Industry
Medical specialties
Address
No.1006, Qihuang Road Chengdu SI China 610219
IPO Date
May 18, 2015
Business
Maccura Biotechnology Co. Ltd. (300463.SZ) engages in the research, development, manufacture, and sale of in vitro diagnostic (IVD) products and related services for medical laboratories primarily in China with international operations. Founded in 1994 and headquartered in Chengdu, China, the company offers a comprehensive portfolio of core products including chemiluminescence immunoassay analyzers and reagents; clinical chemistry reagents and systems for hepatic, renal, cardiac, lipid, coagulation, and special protein testing; automatic hematology analyzers and workstations; molecular diagnostics such as real-time fluorescence quantitative PCR kits, digital PCR systems, and nucleic acid extraction systems; urinalysis analyzers; hemostasis and coagulation analyzers; glycohemoglobin and specific proteins analyzers; biochemistry systems; point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold kits; pathology products; blood transfusion reagents; and SARS-CoV-2 detection kits. Recent developments include the launch of a new Chlamydia pneumoniae IgG antibody detection kit with product registration certification; advancement of the Tianfu International Bio-City IVD Industrial Park project into validation, debugging, and calibration stages; a new product launch contributing an estimated ¥150 million in revenue in 2022; international market expansion into Europe, Southeast Asia, and the US reagents market; and ongoing strategic partnerships to enhance distribution and integrate AI into diagnostics.